Fu-Hua Lin1, Xiang-Heng Zhang1, Ji Zhang1, Zhen-Qiang He1, Hao Duan1, Chao Ke1, Ke Sai1, Xiao-Bing Jiang1, Fuad Al-Nahari1, Shao-Yan Xi2, Yong-Gao Mou3. 1. Department of Neurosurgery, State Key Laboratory of Oncology in South China, Collaborative Innovation, Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou, 510060, China. 2. Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation, Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou, 510060, China. 3. Department of Neurosurgery, State Key Laboratory of Oncology in South China, Collaborative Innovation, Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou, 510060, China. mouyg@sysucc.org.cn.
Abstract
BACKGROUND: Surgical procedures are critical in making a conclusive histopathological diagnosis of primary central nervous system lymphoma (PCNSL), which typically presents contrast-enhancing lesions in magnetic resonance imaging (MRI). The fluorescein sodium-guided technique could enhance tumor visibility. We reported a series of patients with PCNSL underwent fluorescein sodium-guided surgical procedures. PATIENTS AND METHODS: 12 patients clinically considered brain tumors underwent fluorescein sodium-guided surgery in Sun Yat-sen University Cancer Center from March 2016 to July 2017. The age of 4 female and 8 male patients ranges from 39 to 62 years. In 4 patients, corticosteroid had been prescribed before surgery due to intracranial hypertension. After injection of low dose of sodium fluorescein (3-5 mg/kg), the lesions with strong fluorescence staining were identified as the target area for biopsy or resection. RESULTS: Based on the targeted tissues with bright and homogenous fluorescence staining, all 12 patients were conclusively diagnosed as B cell non-Hodgkin's lymphoma (diffuse large cell). The specificity of the specimens sent for frozen section was 86.4% (19/22). No fluorescein sodium associated side effects were observed. CONCLUSION: Fluorescein sodium guided surgery is an effective and safe tool in biopsy or tumor resection in patients suspicious for PCNSL with preoperative MRI presented contrast-enhanced homogenous lesions. Such technique might still be considered in those patients who have been pretreated with corticosteroid.
BACKGROUND: Surgical procedures are critical in making a conclusive histopathological diagnosis of primary central nervous system lymphoma (PCNSL), which typically presents contrast-enhancing lesions in magnetic resonance imaging (MRI). The fluorescein sodium-guided technique could enhance tumor visibility. We reported a series of patients with PCNSL underwent fluorescein sodium-guided surgical procedures. PATIENTS AND METHODS: 12 patients clinically considered brain tumors underwent fluorescein sodium-guided surgery in Sun Yat-sen University Cancer Center from March 2016 to July 2017. The age of 4 female and 8 male patients ranges from 39 to 62 years. In 4 patients, corticosteroid had been prescribed before surgery due to intracranial hypertension. After injection of low dose of sodium fluorescein (3-5 mg/kg), the lesions with strong fluorescence staining were identified as the target area for biopsy or resection. RESULTS: Based on the targeted tissues with bright and homogenous fluorescence staining, all 12 patients were conclusively diagnosed as B cell non-Hodgkin's lymphoma (diffuse large cell). The specificity of the specimens sent for frozen section was 86.4% (19/22). No fluorescein sodium associated side effects were observed. CONCLUSION:Fluorescein sodium guided surgery is an effective and safe tool in biopsy or tumor resection in patients suspicious for PCNSL with preoperative MRI presented contrast-enhanced homogenous lesions. Such technique might still be considered in those patients who have been pretreated with corticosteroid.
Entities:
Keywords:
Biopsy; Corticosteroid pretreatment; Fluorescein sodium; Primary central nervous system lymphoma
Authors: Christian Ewelt; Andrei Nemes; Volker Senner; Johannes Wölfer; Benjamin Brokinkel; Walter Stummer; Markus Holling Journal: J Photochem Photobiol B Date: 2015-05-14 Impact factor: 6.252
Authors: Karl-Michael Schebesch; Julius Hoehne; Christoph Hohenberger; Martin Proescholdt; Markus J Riemenschneider; Christina Wendl; Alexander Brawanski Journal: Acta Neurochir (Wien) Date: 2015-04-01 Impact factor: 2.216
Authors: James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan Journal: J Clin Oncol Date: 2013-04-08 Impact factor: 44.544
Authors: Francesco Acerbi; Morgan Broggi; Karl-Michael Schebesch; Julius Höhne; Claudio Cavallo; Camilla De Laurentis; Marica Eoli; Elena Anghileri; Maura Servida; Carlo Boffano; Bianca Pollo; Marco Schiariti; Sergio Visintini; Cristina Montomoli; Lorenzo Bosio; Emanuele La Corte; Giovanni Broggi; Alexander Brawanski; Paolo Ferroli Journal: Clin Cancer Res Date: 2017-10-10 Impact factor: 12.531
Authors: Meredith S Shiels; Ruth M Pfeiffer; Caroline Besson; Christina A Clarke; Lindsay M Morton; Leticia Nogueira; Karen Pawlish; Elizabeth L Yanik; Gita Suneja; Eric A Engels Journal: Br J Haematol Date: 2016-03-28 Impact factor: 8.615
Authors: Ran Xu; Judith Rösler; Wanda Teich; Josefine Radke; Anton Früh; Lea Scherschinski; Julia Onken; Peter Vajkoczy; Martin Misch; Katharina Faust Journal: J Clin Med Date: 2022-06-10 Impact factor: 4.964
Authors: Karl-Michael Schebesch; Katharina Rosengarth; Alexander Brawanski; Martin Proescholdt; Christina Wendl; Julius Höhne; Christian Ott; Hans Lamecker; Christian Doenitz Journal: Front Surg Date: 2019-10-01